Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.
According to statistical data, the miRNA drug market was estimated at approximately $160.5 million in 2017, with an expected compound annual growth rate (CAGR) of 18.6%.
Otsuka Pharmaceutical announced positive top-line interim data from the phase III clinical trial of sibeprenlimab for treating adults with IgA nephropathy.
Hope Medicine (HopeMed) announced positive interim results from a Phase 2 study of HMI-115 in women with moderate to severe endometriosis-associated pain.
Novo Nordisk announced on its official website the primary results of a Phase 2a clinical trial for its investigational drug monlunabant (previously known as INV-202).
Sanofi announced its entry into the nuclear medicine field through an exclusive licensing agreement with RadioMedix and Orano Med to jointly develop next-generation RLT for rare cancers.